Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $45.60 Average PT from Brokerages

Summary by defenseworld.net
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock…

1 Articles

defenseworld.netdefenseworld.net
Center

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $45.60 Average PT from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

defenseworld.net broke the news in on Monday, March 30, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Del Mar icon

Del Mar

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal